ArticleRNA (New York, N.Y.)2009
Direct selection for ribozyme cleavage activity in cells.
Article in RNA (New York, N.Y.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- A multiplexed, automated evolution pipeline enables scalable discovery and characterization of biosensors.Nature communications · 2021Article
- Intracellular selection of trans-cleaving hammerhead ribozymes.Nucleic acids research · 2019Article
- Engineering protein-protein devices for multilayered regulation of mRNA translation using orthogonal proteases in mammalian cells.Nature communications · 2018Article
- Design and application of cotranscriptional non-enzymatic RNA circuits and signal transducers.Nucleic acids research · 2014Article
- Article
- Article
- Low selection pressure aids the evolution of cooperative ribozyme mutations in cells.The Journal of biological chemistry · 2013Article
- Enhanced group II intron retrohoming in magnesium-deficient Escherichia coli via selection of mutations in the ribozyme core.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- The hammerhead ribozyme: structure, catalysis, and gene regulation.Progress in molecular biology and translational science · 2013Review
- A high-throughput, quantitative cell-based screen for efficient tailoring of RNA device activity.Nucleic acids research · 2012Article
- Engineering biological systems with synthetic RNA molecules.Molecular cell · 2011Review
- Intron cleavage affects processing of alternatively spliced transcripts.RNA (New York, N.Y.) · 2011Article
- Aptamers for allosteric regulation.Nature chemical biology · 2011Review
- In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules.Molecules (Basel, Switzerland) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Selection may prove to be a powerful tool for the generation of functional RNAs for in vivo genetic regulation. However, traditional in vitro selection schemes do not mimic physiological conditions, and in vivo selection schemes frequently use small pool sizes. Here we describe a hybrid in vitro/in vivo selection scheme that overcomes both of these disadvantages. In this new method, PCR-amplified expression templates are transfected into mammalian cells, transcribed hammerhead RNAs self-cleave, and the extracted, functional hammerhead ribozyme species are specifically amplified for the next round of selection. Using this method we have selected a number of cis-cleaving hammerhead ribozyme variants that are functional in vivo and lead to the inhibition of gene expression. More importantly, these results have led us to develop a quantitative, kinetic model that can be used to assess the stringency of the hybrid selection scheme and to direct future experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.